CDC Panel to Vote on Delaying Newborn Hepatitis B Vaccination
The CDC's Advisory Committee on Immunization Practices is set to vote on potentially delaying the hepatitis B vaccine for newborns, a policy in place since 1991.
The Centers for Disease Control and Prevention's (CDC) Advisory Committee on Immunization Practices (ACIP) is scheduled to meet on December 4 and 5 to consider changes to the longstanding recommendation that all newborns receive the hepatitis B vaccine within 24 hours of birth. This policy, established in 1991, has been credited with reducing hepatitis B infections in children by over 95%.
The upcoming vote follows the appointment of Dr. Kirk Milhoan as the new ACIP chair. Dr. Milhoan, a pediatric cardiologist and former U.S. Air Force flight surgeon, was appointed by Health Secretary Robert F. Kennedy Jr., who has restructured the committee with new members.
Despite the vaccine's proven safety and effectiveness, some committee members have raised concerns about potential risks associated with administering the vaccine immediately after birth. Dr. Milhoan suggested that decisions regarding newborn hepatitis B vaccination should be based on individual assessments of the baby's risk for infection.
Public health experts have expressed concern over potential changes to the vaccination schedule. A comprehensive review by the Vaccine Integrity Project, analyzing over 400 studies, found that the current policy has prevented more than 6 million infections and nearly 1 million hospitalizations.
The ACIP's recommendations influence CDC guidelines and can affect insurance coverage for vaccinations. The committee's decision on the hepatitis B vaccine schedule is anticipated to have significant implications for public health policy and newborn care practices.